FinTrust Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$98.9K Buy
637
+569
+837% +$85K 0.02% 439
2024
Q2
$9.31K Hold
68
﹤0.01% 917
2024
Q1
$9.05K Hold
68
﹤0.01% 877
2023
Q4
$9.38K Sell
68
-196
-74% -$25.8K ﹤0.01% 837
2023
Q3
$32.2K Buy
264
+242
+1,100% +$32.2K 0.01% 556
2023
Q2
$3.44K Hold
22
﹤0.01% 935
2023
Q1
$3.44K Hold
22
﹤0.01% 928
2022
Q4
$3.44K Hold
22
﹤0.01% 926
2022
Q3
$3K Hold
22
﹤0.01% 1074
2022
Q2
$3K Hold
22
﹤0.01% 1087
2022
Q1
$3K Hold
22
﹤0.01% 1114
2021
Q4
$4K Hold
22
﹤0.01% 1040
2021
Q3
$3K Hold
22
﹤0.01% 1064
2021
Q2
$3K Hold
22
﹤0.01% 1085
2021
Q1
$3K Hold
22
﹤0.01% 1061
2020
Q4
$3K Sell
22
-65
-75% -$7.92K ﹤0.01% 991
2020
Q3
$10K Hold
87
﹤0.01% 803
2020
Q2
$10K Sell
87
-287
-77% -$30.4K ﹤0.01% 726
2020
Q1
$30K Buy
374
+287
+330% +$29.7K 0.01% 537
2019
Q4
$9K Hold
87
﹤0.01% 756
2019
Q3
$9K Hold
87
﹤0.01% 767
2019
Q2
$9K Sell
87
-4
-4% -$384 ﹤0.01% 748
2019
Q1
$8K Sell
91
-48
-35% -$4.16K ﹤0.01% 822
2018
Q4
$11K Buy
+139
New +$13K 0.01% 744

Other funds holding DGX

FinTrust Capital Advisors's DGX Position: Q3 2024 in Review

FinTrust Capital Advisors increased its Quest Diagnostics (DGX) stake by 837% in Q3 2024, buying an estimated $85K and bringing the position to 637 shares worth $98.9K. The position accounts for 0.02% of the portfolio, ranked #439.

FinTrust Capital Advisors first reported a position in DGX in Q4 2018 and has held it in 24 quarters since. 847 funds tracked by Wall St. Rank hold DGX as of Q3 2024.

  • FinTrust Capital Advisors held 637 shares of Quest Diagnostics worth $98.9K as of Q3 2024.
  • FinTrust Capital Advisors bought 569 Quest Diagnostics shares in Q3 2024, an estimated $85K.
  • Quest Diagnostics made up 0.02% of FinTrust Capital Advisors's portfolio in Q3 2024, its #439 holding.
  • FinTrust Capital Advisors first reported a position in Quest Diagnostics in Q4 2018 and has held it in 24 quarters since.
  • 847 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.